Company intelligence / Profile preview

RE:YOUTH

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

ReYouth Biopharma is a biotechnology company dedicated to the field of regenerative medicine and longevity science. The company focuses on the development of innovative therapies using mesenchymal stem cells (MSCs) and their derived exosomes to treat age-related diseases and promote tissue repair. Their research platform targets cellular senescence and inflammatory pathways to address conditions such as skin aging and osteoarthritis. ReYouth aims to bridge the gap between basic aging research and clinical applications to improve human healthspan through advanced biological interventions.

Therapeutic areas: OtherNeurologyRheumatologyDermatology
Modalities: Stem cell therapyExosome-based therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on RE:YOUTH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RE:YOUTH.

Explore the full profile